South Korea · Delayed Price · Currency is KRW Voronoi Company Description
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea.
Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis.
The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer.
Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
| Country | South Korea |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
Contact Details
Address: 32, Songdo Gwawak-ro Incheon, 21984 South Korea | |
| Phone | 82 3 2219 7838 |
| Website | voronoi.io |
Stock Details
| Ticker Symbol | 310210 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |